New analysis of New York data finds considerable variability in patient product choice, even for patients with the same condition.
Average price growth was high among California for-profit systems (31% over the study period), while non-profit and public systems had lower average price growth (13%) than nonsystem hospitals (15%).
Experts from the private and public sectors convened a panel to improve recruitment for Alzheimer’s clinical trials.
Tools used by insurers and PBMs to contain costs result in fewer patients using NOACs or warfarin
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
Economic incentives to recruit more diverse participants for clinical trials are available and could save the U.S. billions of dollars.
Large dialysis chains charge Medicare Advantage plans 27% more than the traditional, fee-for-service Medicare program.
Using multiple medications with known cardiovascular adverse effects at the same time substantially increases cardiovascular risk.
Schaeffer Center experts argue in a recent op-ed that Los Angeles County hasn’t met the threshold for a mask mandate.
There is little evidence that older adults prescribed benzodiazepines are at increased risk of developing dementia.